Hers
Hers is a national telehealth platform offering FDA-approved weight loss medications including Wegovy and Zepbound. Previously known for $199/mo compounded semaglutide, Hers is phasing out compounded GLP-1s after FDA enforcement actions and a Novo Nordisk patent infringement lawsuit (March 2026). Now transitioning patients to brand-name injectable and oral Wegovy through a direct Novo Nordisk partnership.
Overview
- Consultation Model
- Hybrid
- Headquarters
- San Francisco, CA
- Shipping
- 3-5 business days
- Lab Testing
- No
- Prescriber Info
- licensed provider reviews your submission asynchronously (typically within 24–48 hours) 3.
- Founded
- 2019
Pros
- Clean, women-focused branding and content on hormonal weight management, postpartum weight, and menopause
- Competitive pricing at $199/mo all-in, no hidden membership fees
- Compounded oral semaglutide available
- Fast process
- Backed by a publicly traded company (NYSE: HIMS)
- Free shipping included
Cons
- Async-only consultations
- GLP-1 program is identical to Hims
- No compounded tirzepatide option
- No lifestyle coaching, nutrition guidance, or behavioral support (unlike Calibrate, Found, or WeightWatchers Clinic)
- Compounded semaglutide availability subject to ongoing FDA regulatory action
- More expensive than Ro ($149) and Henry Meds ($149) for compounded semaglutide
Pricing
| Medication | Dose | Price | Billing |
|---|---|---|---|
| semaglutide | 0.25-2.4mg/week | $199 | monthly |
| tirzepatide | 2.5-15mg/week | $399 | monthly |